Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

Scientific reports - 25 Nov 2016

Capelli Laura, Casadei Gardini Andrea, Scarpi Emanuela, Frassineti Giovanni Luca, Saragoni Luca, Puccetti Maurizio, Scartozzi Mario, Giannini Massimo, Tamberi Stefano, Corbelli Jody, Ulivi Paola

Abstract excerpt

Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in SCAC. In this study we analyzed NRAS status (exons 2-4) by Pyrosequencing in a case series of 50 SCAC patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Disease-Free Survival

Share to GTP Phosphohydrolases

Share to Kaplan-Meier Estimate

Share to Membrane Proteins

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 27886225
DOI: 10.1038/srep37621
PMCID: PMC5122846

Genes

EGFR
NRAS
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).PMID 27886225Read ↗

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

KRAS and BRAF mutations in anal carcinoma.Semantic proximity Read ↗

EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.Semantic proximity Read ↗

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?Semantic proximity Read ↗

Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.Semantic proximity Read ↗

Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention.Semantic proximity Read ↗

Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.Semantic proximity Read ↗

NRAS mutations are rare in colorectal cancer.Semantic proximity Read ↗

KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.Semantic proximity Read ↗

K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?Semantic proximity Read ↗

Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples.Semantic proximity Read ↗

No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.